A promising new medication may soon expand treatment options for people living with IgA nephropathy, a chronic autoimmune disease that damages the kidneys. Researchers recently reported encouraging results from a late‑stage clinical trial evaluating an experimental drug called povetacicept. The therapy is designed to target abnormal immune signals that drive the disease.
IgA nephropathy occurs when immune proteins called immunoglobulin A (IgA) accumulate in the kidneys. These deposits trigger inflammation that gradually damages the tiny filtering units responsible for cleaning waste from the blood. Over time, this damage can lead to reduced kidney function and, in severe cases, kidney failure.
In the recent trial, patients receiving povetacicept experienced a major reduction in proteinuria—the leakage of protein into the urine that signals kidney damage. After 36 weeks of treatment, protein levels in urine fell by about 52%, compared with only a small reduction in the placebo group. Researchers also observed a significant decrease in harmful antibody activity linked to the disease.
Importantly, the drug appeared generally safe and well tolerated. Most side effects reported during the trial were mild to moderate. This is encouraging for patients because many current treatments rely heavily on broad immune suppression, which can carry significant long‑term risks.
The therapy works by blocking two immune system signals that drive B cells—the immune cells responsible for producing antibodies involved in autoimmune attacks. By dampening these signals, the drug may reduce the production of abnormal IgA antibodies and limit further kidney inflammation.
The ongoing study is still tracking long‑term outcomes to determine whether the drug can slow or prevent permanent kidney damage. If those results remain positive, the manufacturer plans to seek regulatory approval in the near future.
For patients and families affected by IgA nephropathy, this research represents a hopeful step toward more targeted therapies that address the underlying immune dysfunction rather than only treating symptoms.
Key Patient Takeaway:
A new targeted therapy may significantly reduce kidney damage markers in IgA nephropathy, offering hope for more effective and safer treatments.
Read More 👉 Vertex to seek US approval after promising late-stage results for kidney drug